project . 2016 - 2022 . Closed

A randomized controlled trial of influenza vaccine to prevent adverse vascular events.

UK Research and Innovation
  • Funder: UK Research and InnovationProject code: MR/N005759/1
  • Funded under: MRC Funder Contribution: 3,039,500 GBP
  • Status: Closed
  • Start Date
    01 Mar 2016
    End Date
    30 Mar 2022
Description
Cardiovascular disease is a leading cause of death globally estimated to be responsible for approximately 17 million deaths annually. Heart disease and stroke account for nearly one third of all deaths and are a major cause of hospitalization. Patients with congestive heart failure (CHF) are at particularly high risk. Clinical trials demonstrate that nearly one third of patients with CHF will experience a myocardial infarction (MI), stroke, or hospitalization for CHF. Observational studies have established an association between influenza infection and major adverse vascular events . It follows that vaccinating such a high risk group as patients with CHF against...
Description
Cardiovascular disease is a leading cause of death globally estimated to be responsible for approximately 17 million deaths annually. Heart disease and stroke account for nearly one third of all deaths and are a major cause of hospitalization. Patients with congestive heart failure (CHF) are at particularly high risk. Clinical trials demonstrate that nearly one third of patients with CHF will experience a myocardial infarction (MI), stroke, or hospitalization for CHF. Observational studies have established an association between influenza infection and major adverse vascular events . It follows that vaccinating such a high risk group as patients with CHF against...
Any information missing or wrong?Report an Issue